Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07117383 · ClinicalTrials.gov registry record · Phase 1
Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject
A Phase 1 study, sponsored by Aspargo Labs.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07117383: Clinical Trial Phase 1 study, sponsored by Aspargo Labs.
NCT07117383 is a Phase 1 study that has not yet begun recruiting, run by Aspargo Labs. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07117383, a Phase 1 study, has not yet begun recruiting, sponsored by Aspargo Labs.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare how different sildenafil formulations are absorbed and tolerated in healthy adult males under fed conditions. The main questions it aims to answer are: Do Hezkue and Hezkue Turbo differ in absorption compared to other commercial sildenafil products? Are there any differences in safety or tolerability between the products? Researchers will compare multiple formulations to evaluate differences in drug absorption and side effects.
Primary Outcome
Measurement of the time (Tmax) to reach maximum observed plasma concentration of sildenafil following a single oral dose under fed conditions.
Interventions
- DEVICE ASP-001.1
- DRUG ASP-001
- DRUG Commercial Sildenafil and Sildenafil/Tadalafil Products
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What is known before NCT07117383 opens enrollment
NCT07117383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 3 interventions - of which ASP-001.1 is the first listed.
NCT07117383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07117383 about?
NCT07117383 is a clinical study titled "Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject". The goal of this clinical trial is to compare how different sildenafil formulations are absorbed and tolerated in healthy adult males under fed conditions. The main questions it aims to answer are: Do Hezkue and Hezkue Turbo differ in absorption compared to other commercial sildenafil products? Ar...
What is the current status of trial NCT07117383?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-01. Estimated completion is 2026-03.
What interventions are being tested in trial NCT07117383?
The interventions under investigation include: ASP-001.1 (DEVICE), ASP-001 (DRUG), Commercial Sildenafil and Sildenafil/Tadalafil Products (DRUG).
Who is sponsoring clinical trial NCT07117383?
This trial is sponsored by Aspargo Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07117383's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia